These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 18288997)

  • 21. Targeting angiogenesis in esophagogastric adenocarcinoma.
    Okines AF; Reynolds AR; Cunningham D
    Oncologist; 2011; 16(6):844-58. PubMed ID: 21632459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical pharmacokinetics of tyrosine kinase inhibitors.
    van Erp NP; Gelderblom H; Guchelaar HJ
    Cancer Treat Rev; 2009 Dec; 35(8):692-706. PubMed ID: 19733976
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent advances in the systemic treatment of metastatic papillary renal cancer.
    Chowdhury S; Choueiri TK
    Expert Rev Anticancer Ther; 2009 Mar; 9(3):373-9. PubMed ID: 19275514
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Focus on GIST management].
    Tardieu M; Dômont J; Cioffi A; Bonvalot S; Le Cesne A
    Bull Cancer; 2010 Jun; 97(6):723-31. PubMed ID: 20483709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors].
    Thomas X
    Bull Cancer; 2007 Oct; 94(10):871-80. PubMed ID: 17964981
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
    Horn L; Sandler AB
    Clin Lung Cancer; 2009 Mar; 10 Suppl 1(Suppl 1):S7-16. PubMed ID: 19362948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
    Erdem L; Giovannetti E; Leon LG; Honeywell R; Peters GJ
    Curr Top Med Chem; 2012; 12(15):1649-59. PubMed ID: 22978339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
    Gridelli C; Maione P; Del Gaizo F; Colantuoni G; Guerriero C; Ferrara C; Nicolella D; Comunale D; De Vita A; Rossi A
    Oncologist; 2007 Feb; 12(2):191-200. PubMed ID: 17296815
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia.
    Hu S; Niu H; Minkin P; Orwick S; Shimada A; Inaba H; Dahl GV; Rubnitz J; Baker SD
    Mol Cancer Ther; 2008 May; 7(5):1110-20. PubMed ID: 18483300
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of antiangiogenesis therapy: bevacizumab and beyond.
    Cortés-Funes H
    Clin Transl Oncol; 2009 Jun; 11(6):349-55. PubMed ID: 19531449
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition.
    Force T; Krause DS; Van Etten RA
    Nat Rev Cancer; 2007 May; 7(5):332-44. PubMed ID: 17457301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
    Muriel C; Esteban E; Corral N; Fonseca PJ; Luque M; Berros JP; Fernández Y; Blay P; Fra J; Villanueva N; Sanmamed M; Pardo P; Izquierdo M; Vieitez JM; Estrada E; Lacave ÁJ
    Clin Transl Oncol; 2010 Aug; 12(8):562-7. PubMed ID: 20709657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Targeted therapies and their indications in solid neoplasias].
    Dreyer C; Raymond E; Faivre S
    Rev Med Interne; 2009 May; 30(5):416-24. PubMed ID: 19299048
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New developments in multitargeted therapy for patients with solid tumours.
    Le Tourneau C; Faivre S; Raymond E
    Cancer Treat Rev; 2008 Feb; 34(1):37-48. PubMed ID: 17983706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tyrosine kinase inhibitors and the thyroid.
    Sherman SI
    Best Pract Res Clin Endocrinol Metab; 2009 Dec; 23(6):713-22. PubMed ID: 19942148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted therapies in metastatic renal cancer in 2009.
    Bastien L; Culine S; Paule B; Ledbai S; Patard JJ; de la Taille A
    BJU Int; 2009 May; 103(10):1334-42. PubMed ID: 19338565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current and future management of GIST.
    Blanke C
    Clin Adv Hematol Oncol; 2006 Aug; 4(8):582-3. PubMed ID: 17099615
    [No Abstract]   [Full Text] [Related]  

  • 38. Kinase Inhibitors in Multitargeted Cancer Therapy.
    Gentile C; Martorana A; Lauria A; Bonsignore R
    Curr Med Chem; 2017; 24(16):1671-1686. PubMed ID: 28078996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Novelties in the treatment for advanced renal-cell cancer].
    Maráz A
    Orv Hetil; 2011 Apr; 152(17):655-62. PubMed ID: 21464023
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted therapy for metastatic renal cell carcinoma.
    Motzer RJ; Bukowski RM
    J Clin Oncol; 2006 Dec; 24(35):5601-8. PubMed ID: 17158546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.